We use cookies to improve site performance and enhance your user experience. If you'd like to disable cookies on this device, please see our cookie management page.
If you close this message or continue to use this site, you consent to our use of cookies on this devise in accordance with our cookie policy, unless you disable them.

2 FREE PAGES remain this month
for more website access

You can view 2 more articles. Please register to view this article, or subscribe for share tips and full online access.

Boardroom Talk: Summit Therapeutics' long road to drug approval

Boardroom Talk: Summit Therapeutics' long road to drug approval

Summit Therapeutics (SUMM) is a small-cap biotech company with two drugs in clinical trials at either end of the new drugs space: a low risk, lower reward antibiotic and a high risk, higher reward Duchenne Muscular Dystrophy cure. Does this make it an ideal biotech investment? Megan Boxall investigates.

For all our other podcasts, including the latest IC Questions special on profit warnings in 2017 and more episdoes of Boardroom Talk, go to www.investorschronicle.co.uk/podcast

visible-status-Standard story-url-Summit_podcast_200317.xml

By Megan Boxall,
20 March 2017

Print this article

Related Companies

Advertiser reports

Register today and get...

Register today and get...
Please note terms & conditions apply